Dr. Kirson Discusses the LUNAR Study in Advanced NSCLC

LUNAR: Tumor Treating Field (TTFields) therapy with SOC in mNSCLC following platinum failureПодробнее

Dr. Rekamp Discusses a Phase II study MK-2206 plus Erlotinib in NSCLCПодробнее

Treatment resistance as a key challenge in patients with advanced NSCLCПодробнее

Treatment sequecing strategies in advanced NSCLCПодробнее

GRACEcast - LCVL - What are the leading first line treatment options for advanced NSCLC harboring anПодробнее

Treatment for Patients with Advanced NSCLC - Leading Developments & Current Questions in Lung CancerПодробнее

Background of SANOVO trial for patients with advanced NSCLCПодробнее

The LUNAR study: TTFields for NSCLCПодробнее

NSCLC trial updates at ESMO 2022: ADAURA, DESTINY-Lung02, KN189, KN407 & POSEIDONПодробнее

Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial CarcinomaПодробнее

A new standard of care for advanced lung cancer: what’s next for pembrolizumab?Подробнее

Improving outcomes for patients with metastatic NSCLC with immunotherapyПодробнее

Current and future approaches of immunotherapy for NSCLCПодробнее

Unanswered questions in treating NSCLC with radiotherapyПодробнее

Tumor Treating Fields: The Fourth Treatment Modality - interview with Eilon D. Kirson, MD, PhD.Подробнее

Dr. Sznol Discusses Immunotherapy Combinations in RCCПодробнее

Clinical outcomes of immunotherapy after radiographic progression in advanced NSCLCПодробнее

The JAVELIN 100 study: a trial to improve lung cancer treatmentПодробнее